Marcel Wacker
YOU?
Author Swipe
View article: 1239 Uncovering the dark side of the immunopeptidome
1239 Uncovering the dark side of the immunopeptidome Open
View article: IMMU-32. The intra-tumoral heterogeneity of T cell antigens in glioblastoma
IMMU-32. The intra-tumoral heterogeneity of T cell antigens in glioblastoma Open
The limited effectiveness of current glioblastoma treatments can be attributed, at least in part, to the intricate intra- and inter-tumoral heterogeneity. To entangle this complexity, we employed a multi-omics approach, focusing on the imm…
View article: TAPBPR promotes editing of the HLA-B44 peptide repertoire, increasing the presentation of peptides containing a C-terminal tryptophan
TAPBPR promotes editing of the HLA-B44 peptide repertoire, increasing the presentation of peptides containing a C-terminal tryptophan Open
Major histocompatibility complex class I (MHC-I) molecules play a key part in the adaptive immune response by presenting antigens to CD8 + T cells. The high degree of polymorphism in MHC-I leads to significant variation in their dependence…
View article: MHCquant2 refines immunopeptidomics tumor antigen discovery
MHCquant2 refines immunopeptidomics tumor antigen discovery Open
Confident identification of human leukocyte antigen (HLA)-presented peptides is crucial for advancing cancer immunotherapy. We present MHCquant2, a scalable and modular Nextflow pipeline integrated into nf-core as a reproducible, portable,…
View article: PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development Open
Background Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the dev…
View article: MHCquant2 refines immunopeptidomics tumor antigen discovery
MHCquant2 refines immunopeptidomics tumor antigen discovery Open
The identification of human leukocyte antigen (HLA)-presented peptides as targets of anti-cancer T cell response is pivotal for the development of novel immunotherapies. Mass spectrometry (MS)-based immunopeptidomics enables the detection …
View article: PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development Open
Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of…
View article: Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients Open
Cancer peptide vaccination represents a promising therapeutic approach, but has been hampered by lack of suitable antigens and restricted applicability due to different HLA backgrounds of individual patients. We here introduce a novel ware…
View article: iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens Open
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia among adults in Western countries. Despite the introduction of targeted therapies, including first-line Bruton’s tyrosine kinase inhibitor (BTKi) treatment, CLL remains…
View article: TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification Open
View article: 1463 The intra-tumoral spatial heterogeneity of T cell antigens in glioblastoma: An integrated multi-omics approach
1463 The intra-tumoral spatial heterogeneity of T cell antigens in glioblastoma: An integrated multi-omics approach Open
Background Glioblastoma is the most common primary malignant neoplasm of the central nervous system in adults. Current treatment options comprise maximal surgical resection followed by radiation and/or chemotherapy with temozolomide. These…
View article: 872 Combined multi-omics analysis delineates the impact of epigenetic therapies on the immunopeptidome of acute myeloid leukemia
872 Combined multi-omics analysis delineates the impact of epigenetic therapies on the immunopeptidome of acute myeloid leukemia Open
Background Epigenetic modifying therapies, including hypomethylating agents (HMA) and histone deacetylase (HDAC) inhibitors, have shown promising results in the treatment of acute myeloid leukemia (AML). Recent data point to an immunologic…
View article: Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency Open
T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and…
View article: Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics
Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics Open
Introduction Mass spectrometry-based immunopeptidomics is the only unbiased method to identify naturally presented HLA ligands, which is an indispensable prerequisite for characterizing novel tumor antigens for immunotherapeutic approaches…
View article: Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma Open
View article: Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Supplementary Figures S1-S5 Supplementary Tables S1-S3 revised
View article: Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed an…
View article: Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Figures S1-S5 and Tables S1-S3 from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Supplementary Figures S1-S5 Supplementary Tables S1-S3 revised
View article: Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Data from Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed an…
View article: timsTOF mass spectrometry-based immunopeptidomics refines tumor antigen identification
timsTOF mass spectrometry-based immunopeptidomics refines tumor antigen identification Open
T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for the direct identifica…
View article: IMMU-28. THE INTRA-TUMORAL SPATIAL HETEROGENEITY OF T CELL ANTIGENS IN GLIOBLASTOMA: AN INTEGRATED MULTI-OMICS APPROACH
IMMU-28. THE INTRA-TUMORAL SPATIAL HETEROGENEITY OF T CELL ANTIGENS IN GLIOBLASTOMA: AN INTEGRATED MULTI-OMICS APPROACH Open
This study investigates the intratumoral heterogeneity of T cell antigen presentation in 15 newly diagnosed glioblastoma patients. Our multi-omics approach includes mass spectrometry-based immunopeptidome analysis, next-generation sequenci…
View article: The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma Open
View article: Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency Open
T-cell immunity is central for the control of COVID-19, in particular in patients incapable to mount a humoral immune response. We previously reported on the favorable safety profile and efficacy in terms of induction of SARS-CoV-2-specifi…
View article: A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity Open
View article: Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell Immunity
Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell Immunity Open
T-cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T-cell epitopes derived from various viral proteins, combined with the toll-like receptor 1/2 agonist XS15…
View article: Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer Open
Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed and SARS-CoV-2–infected …
View article: T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals Open
Longitudinal analysis identifies SARS-CoV-2 peptide targets of durable memory T cell responses in COVID-19 convalescent individuals.
View article: Pre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients
Pre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients Open
Cancer patients, in particular patients with hematological malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T cell responses in unexposed and S…
View article: Differential kinetics of T cell and antibody responses delineate dominant T cell epitopes in long-term immunity after COVID-19
Differential kinetics of T cell and antibody responses delineate dominant T cell epitopes in long-term immunity after COVID-19 Open
Long-term immunity to SARS-CoV-2 is crucial for the development of herd immunity and the aim of vaccination approaches. Reports on rapidly decreasing antibody titers question the efficacy of humoral immunity. The relevance of T cell memory…
View article: SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition
SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition Open
The SARS-CoV-2 pandemic calls for the rapid development of diagnostic, preventive, and therapeutic approaches. CD4+ and CD8+ T cell-mediated immunity is central for control of and protection from viral infections…